Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QGE7 | ISIN: US04683R1068 | Ticker-Symbol:
NASDAQ
31.03.25
21:21 Uhr
3,005 US-Dollar
+0,085
+2,91 %
1-Jahres-Chart
ATEA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ATEA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ATEA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAtea Pharmaceuticals ergreift Maßnahmen zur Steigerung des Aktionärswerts3
MiAtea Pharmaceuticals takes steps to boost shareholder value1
MiAtea Pharmaceuticals cuts workforce by ~25% in Q11
MiAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value930BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...
► Artikel lesen
24.03.Atea Pharmaceuticals, Inc. - 8-K, Current Report-
21.03.Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Issues Statement Regarding Director Nominations358BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
► Artikel lesen
21.03.Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory1
07.03.Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial2
ATEA PHARMACEUTICALS Aktie jetzt für 0€ handeln
07.03.Atea Pharmaceuticals offloads a quarter of its workforce, gears up for phase 3 HCV trials2
06.03.Atea Pharmaceuticals GAAP EPS of -$0.40 misses by $0.032
06.03.Atea Pharmaceuticals, Inc. - 10-K, Annual Report-
24.02.Atea Pharmaceuticals appoints Arthur Kirsch to Board2
24.02.Atea Pharmaceuticals, Inc. - 8-K, Current Report-
24.02.Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors151BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
► Artikel lesen
01.02.Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Decreases By 12.9%1
16.12.24Atea Pharmaceuticals engages Evercore to explore partnerships1
16.12.24Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships2
04.12.24After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study1
04.12.24Atea Pharmaceuticals meldet hohe Wirksamkeit in Phase-2-Studie zur HCV-Behandlung1
04.12.24Atea Pharmaceuticals reports high efficacy in Phase 2 HCV treatment study2
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1